19/12/2015: First encouraging results for EBOVAC on Ebola Vaccine Regimen

The clinical data analysis shows very encouraging results with an antibody response produced by the prime-boost Ebola vaccine regimen in 100 percent of healthy volunteers that was sustained 8 months following immunization. 

View press release here.


08/12/2015: Inserm has launched its campaign to enrol 300 volunteers for Phase 2 trials.

View press release here.


15/07/2015: The University of Oxford has started enrolling volunteers for Phase 2 trials.

View press release here.


16/01/2015: IMI2: First innovative medicines Initiative Ebola projects get underway:





  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA

    Press release and more information

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

  • 29 February 2016

    The first subject was randomized on 10 December 2016 at Makerere University in Uganda.

  • 29 February 2016

    The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research